Thermo Fisher, Cellectis Enter Licensing Pact Covering TAL Nucleases | GenomeWeb

NEW YORK (GenomeWeb) – Thermo Fisher Scientific and French firm Cellectis have inked a series of agreements covering the use of TAL nucleases for a variety of applications.

Under the agreements, Thermo Fisher gains a worldwide license under Cellectis' IP rights to use TAL nucleases outside the therapeutics field with exclusive rights to grant sublicenses in research and development, bioproduction, and applied markets. Thermo Fisher's Life Technologies business markets TAL nucleases under the brand name TALEN for these applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.